The United Kingdom and the United States have signed a key bilateral deal that will guarantee zero levies on UK drug products going into the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to boost funding on pharmaceuticals through the National Health Service (NHS). This commitment ensures that duties on these key exports will remain at nothing for a period of 36 months.
This deal is in response to earlier threats to dramatically increase tariffs on branded drug imports, with figures floated as high as 100%.
"This agreement between the United Kingdom reinforces the global environment for innovative medicines and brings much-needed balance to transatlantic drug exports," a statement declared.
Commercial Importance
Medicines are one of the the United Kingdom's most significant goods shipped to the United States, which is clearly the primary destination for leading British pharmaceutical firms.
Export figures show that in the year to the end of last September, the UK sold pharmaceutical products worth £11.1bn to the US. This figure accounted for a significant portion of British export trade in that period.
"This deal safeguards work, stimulates funding and sets the stage for the UK to become a international leader for medical research," a minister remarked.
Key NHS Changes
The pact involves several specific pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise total public funding on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments topped twenty percent.
Broader Context
This agreement comes amid a long-running row between the sector and the UK government over spending levels and NHS adoption.
The disagreement were heightened by claims that American consumers were paying significantly more for the same drugs than patients in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward American operations.
One official stated that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
